AFFILIATIONS
1 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Beijing, China
2 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Beijing, China
3 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Beijing, China
4 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Beijing, China
5 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Beijing, China
6 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Beijing, China
7 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Beijing, China
8 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Beijing, China
9 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Beijing, China
10 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Beijing, China
11 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Beijing, China
12 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Beijing, China
13 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Beijing, China
14 Peking University Third Hospital Education Department, Beijing, China, Beijing, China
15 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Beijing, China
16 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China, Beijing, China, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China, Beijing, China
ABSTRACT
Longitudinal Trajectories of Lipids Predict Post-transplant Relapse and Survival in Acute Myeloid Leukemia
Background: Dyslipidemia is common after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the long-term dynamic patterns of circulating lipids and their prognostic implications on post-transplant outcomes remain poorly characterized. This study aimed to identify distinct longitudinal lipid trajectories and assess their associations with post-transplant clinical endpoints in a consecutive cohort of patients with acute myeloid leukemia (AML) receiving allo-HSCT.
Methods: A total of 1280 AML patients with available pre-transplant lipid profiles, including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG), and at least one lipid measurement at designated post-transplant time points (i.e., +1, +3, +6, +9, +12, +18, and +24 months), were initially enrolled. Lipid measurements obtained after lipid-lowering treatment and secondary allo-HSCT were excluded from the description of longitudinal trends. Patients receiving lipid-lowering agents or post-relapse lipid data were excluded from trajectory analysis. Group-based trajectory modeling (GBTM) was performed to identify distinct single-lipid trajectories for TC, LDL-C, HDL-C, and TG. Given that TC is largely composed of LDL-C, HDL-C, and TG-derived very low-density lipoprotein cholesterol, group-based multi-trajectory modeling (GBMTM) was used to identify multi-trajectories for TG, LDL-C, and HDL-C. The study was approved by the institutional review board of Peking University of People’s Hospital and was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants in the study.
Results: Among the 1,265 patients with available lipid data within the first 2 years after allo-HSCT, TC and LDL-C exhibited a persistent upward trend, TG increased transiently in the early post-transplant period and then declined, while HDL-C showed an initial decrease followed by gradual recovery during the first 2 years after allo-HSCT. A total of 1169 patients were included for lipid trajectory analysis. Three distinct TC trajectories, two trajectories for each of LDL-C, TG, and HDL-C were identified. A persistently high HDL-C trajectory was independently associated with reduced risks of minimal residual disease (MRD) positivity (HR = 0.61; 95% CI, 0.39–0.95; P = 0.030), relapse (HR = 0.55; 95% CI, 0.35–0.85; P = 0.008), and inferior leukemia-free survival (LFS) (HR = 0.58; 95% CI, 0.39–0.85; P = 0.004). Conversely, a high TG trajectory was associated with increased non-relapse mortality (NRM) (HR = 2.33; 95% CI, 1.15–4.72; P = 0.019). GBMTM identified five combined lipid trajectories. Compared with patients exhibiting a favorable metabolic profile characterized by persistently high HDL-C and stable low TG levels (Group 1, n = 221), patients with modestly elevated TG and low HDL-C recovery (Groups 2 and 3, n = 776) had increased risks of MRD positivity (HR = 1.86; 95% CI, 1.13–3.06; P = 0.014), relapse (HR = 1.84; 95% CI, 1.13–3.00; P = 0.015), and inferior LFS (HR = 1.69; 95% CI, 1.12–2.55; P = 0.013). Notably, patients with a high-risk metabolic phenotype characterized by sustained hypertriglyceridemia and persistently low HDL-C (Group 5, n = 84) exhibited significantly increased all-cause mortality (HR = 2.12; 95% CI, 1.04–4.31; P = 0.038).
Conclusions: This study identifies distinct longitudinal lipid trajectories associated with clinical outcomes after allo-HSCT in AML. Dynamic HDL-C and TG patterns provide independent prognostic information for relapse, survival, and non-relapse mortality. Serial lipid monitoring represents an accessible and clinically feasible approach for risk stratification after transplantation. Prospective studies are warranted to determine whether targeted modulation of lipid abnormalities can improve long-term outcomes in allo-HSCT recipients.